Medisi America
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES

Medtronic announces Infuse spine trial

By Medisi America on 10 octubre, 2019

Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures.

The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, after the FDA approved a separate study in 2017 for posterolateral fusion procedures, which is still enrolling patients. If you want to read more about this news, click here. 

Posted in News.
Share
←  Newer‘Electronic tongues’ may help diagnose early stage bladder cancer
Older  →AI-enhanced ECGs may soon assess overall health

Entradas recientes

  • COFEPRIS Evolves
  • COFEPRIS Challenges 2020
  • ResMed ventilators recall is Class I
  • Finding a non-invasive way to predict effectiveness of cancer therapy.

NEWS

  • Conferences
  • News
  • Science
  • Technology

Deja una respuesta Cancelar la respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Related Posts

  • 10 octubre, 2019

    ‘Electronic tongues’ may help diagnose early stage bladder cancer

    New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe …

  • 30 diciembre, 2019

    Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

    «The Food and Drug Administration (FDA, Agency) identified a list of class I devices and class II devices that are now exempt from premarket notification requirements, subject to certain limitations. FDA published the lists of final determinations in accordance with procedures established by the 21stCentury Cures Act (Cures Act). Although each classification regulation for each …

  • 10 octubre, 2019

    Human trials could start soon on Adam’s 3D printed bone grafts

    Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year. Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology …

  • 18 junio, 2019

    5 Pediatric Orthopedic Devices you need to know

    The National Capital Consortium for Pediatric Device Innovation recently recognized five pediatric orthopedic devices that could improve scoliosis treatment, clubfoot assessment, and surgical imaging. If you want to read more about this news click here.

  • © 2026 MEDISI America - All rights reserved
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES